ASCO26: David Reardon, MD, Glioblastoma Vaccine - Summary - MDSpire

ASCO26: David Reardon, MD, Glioblastoma Vaccine

Dana-Farber Cancer Institute's Dr. David Reardon reports on data showing a phase 1 trial looking at a personalized vaccine plus pembrolizumab sparked tumor-targeting T cells in glioblastoma and was linked to longer survival in immune responders.

  • July 1, 2026

Share

Objective:

To report on a phase 1 trial evaluating a personalized vaccine combined with pembrolizumab in glioblastoma patients.

Approach:
  • Trial Design: Phase 1 trial assessing the efficacy of a personalized vaccine alongside pembrolizumab.
Key Findings:
  • The combination of the personalized vaccine and pembrolizumab sparked tumor-targeting T cells in glioblastoma.
  • Immune responders were linked to longer survival rates.
Interpretation:

The findings suggest a potential benefit of the personalized vaccine in glioblastoma treatment.

Conclusion:

The trial indicates promising results for the use of personalized vaccines in glioblastoma.

Original Source(s)

ASCO26: David Reardon, MD, Glioblastoma Vaccine

  • July 1, 2026

Related Content

ASCO26: Atish Choudhury, MD, PhD, A-DREAM/Alliance A032101

A-DREAM/Alliance A032101 study presented by Dana-Farber Cancer Institute's Dr. Atish Choudhury shows 41% of favorable responders to testosterone suppression plus androgen receptor pathway inhibitor remaining treatment-free with testosterone recovery at 18 months after treatment interruption.

  • July 1, 2026

  • 1 min
Case report: Secretory carcinoma of the breast with ETV6-NTRK3 fusion: clinicopathological features and molecular confirmation by FISH in two cases

ASCO26: Alicia Morgans, MD, MPH, ARACOG

Dr. Alicia Morgans of Dana-Farber Cancer Institute reported at #ASCO26 that ARACOG found darolutamide was associated with less decline in cognitive testing than enzalutamide, which may help guide treatment choice.

  • July 1, 2026

  • 1 min